- Home
- RQI vs VRDN Comparison
RQI vs VRDN Comparison
Compare RQI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- VRDN
- Stock Information
- Founded
- RQI 2002
- VRDN 2006
- Country
- RQI United States
- VRDN United States
- Employees
- RQI N/A
- VRDN N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- VRDN Medical Specialities
- Sector
- RQI Finance
- VRDN Health Care
- Exchange
- RQI Nasdaq
- VRDN Nasdaq
- Market Cap
- RQI 1.7B
- VRDN 1.6B
- IPO Year
- RQI N/A
- VRDN N/A
- Fundamental
- Price
- RQI $12.93
- VRDN $16.27
- Analyst Decision
- RQI
- VRDN Buy
- Analyst Count
- RQI 0
- VRDN 12
- Target Price
- RQI N/A
- VRDN $36.44
- AVG Volume (30 Days)
- RQI 432.6K
- VRDN 979.5K
- Earning Date
- RQI 01-01-0001
- VRDN 03-04-2025
- Dividend Yield
- RQI 8.20%
- VRDN N/A
- EPS Growth
- RQI N/A
- VRDN N/A
- EPS
- RQI N/A
- VRDN N/A
- Revenue
- RQI N/A
- VRDN $302,000.00
- Revenue This Year
- RQI N/A
- VRDN $3.30
- Revenue Next Year
- RQI N/A
- VRDN N/A
- P/E Ratio
- RQI N/A
- VRDN N/A
- Revenue Growth
- RQI N/A
- VRDN N/A
- 52 Week Low
- RQI $9.17
- VRDN $11.40
- 52 Week High
- RQI $12.64
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- RQI 55.60
- VRDN 36.43
- Support Level
- RQI $12.78
- VRDN $15.62
- Resistance Level
- RQI $13.05
- VRDN $18.15
- Average True Range (ATR)
- RQI 0.17
- VRDN 0.91
- MACD
- RQI 0.00
- VRDN -0.20
- Stochastic Oscillator
- RQI 76.92
- VRDN 14.48
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.